Related Experiment Video
Updated: Jul 13, 2026
08:50
Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Recovery from neuromuscular blockade: a survey of practice
1Southampton General Hospital, Southampton SO16 6YD, UK.
Anaesthesia
|July 20, 2007
Summary
UK anaesthetists lack consensus on confirming neuromuscular blockade reversal. Current practices show confusion, limited understanding of monitors, and a need for clearer national guidelines on recovery monitoring.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Neuromuscular blockade reversal adequacy lacks standardized assessment in the UK.
- Current clinical practices for confirming recovery are inconsistent among anesthesiologists.
Purpose of the Study:
- To survey current UK anesthesiology departments to determine practices for indicating reversal adequacy from neuromuscular blockade.
- To identify the clinical parameters and monitors used by anesthesiologists to assess neuromuscular recovery.
Main Methods:
- A survey was conducted across 12 UK anesthetic departments.
- Participants detailed their use of neuromuscular blockade monitors or preferred clinical signs for recovery assessment.
Main Results:
- No consensus exists among UK anesthesiologists regarding reliable clinical signs for neuromuscular recovery.
- There is a noted lack of understanding and inappropriate application of clinical signs for recovery.
- Limited knowledge of recommended train-of-four ratios was observed even where quantitative monitors are available.
- Overall confusion exists regarding the best methods to confirm recovery, with insufficient reliance on quantitative monitors.
Conclusions:
- There is a significant lack of clarity and consensus in UK national guidelines for monitoring neuromuscular function post-anesthesia.
- Current standards for neuromuscular blockade reversal assessment require re-evaluation, considering advancements in nerve stimulator technology.
- Improved guidelines and education are needed to ensure safe and effective patient recovery from neuromuscular blockade.
Related Concept Videos
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...